Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

By María E. Reig1 , 2, Z. Mariño, C. Perelló, M. Iñarrairaegui, Andrea Ribeiro, S. Lens, A. Díaz, R. Vilana, A. Darnell, M. Varela and 4 more. Journal of Hepatology, 2016

967 citations recorded by the source corpus.

Subfields: Hepatology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/8f5d7001bfd0114b000f398bd67d3eb8eb89da05

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

In Pathology and Forensic Medicine

Andrew X. Zhu

Citations in the corpus

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2018, methodology): “The single-center study included patients with HCV infection and treated HCC who achieved a complete response.(39) A total of 58 patients with treated HCC received DAA and after a median follow-up of 5.”
EASL Recommendations on Treatment of Hepatitis C 2018. (2018, methodology): “curative procedures and were subsequently treated with IFNfree regimens and cured from HCV in most cases.(144,145) The sta-”
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases (2019, methodology): “The single-center study included patients with HCV infection and treated HCC who achieved a complete response.(39) A total of 58 patients with treated HCC received DAA and after a median follow-up of 5.”